Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

A cancer drug class best known for attacking tumors may also help your immune system remember them better. Researchers at ...

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity decreases, scans show improvement, and patient lifespans are prolonged for some ...

U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated ...

FDA fast track covers ART6043 plus olaparib in PARP inhibitor–naïve gBRCAm, HER2-negative locally advanced/metastatic breast cancer, enabling earlier FDA engagement and potential priority ...

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients can interact and drive resistance to certain drugs ...

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients ...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...

Tarpon Springs, Florida Monday, March 9, 2026, 15:00 Hrs [IST] ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...